Hologic (HOLX) Osake Kurssi
Hologic Kurssi
Viimeisten 19 vuoden aikana Hologicn liikevaihto kasvoi 12,2 % vuodessa ja ylsi 4,10 Mrd. USD:een. Osakekohtainen tulos on kasvanut 12,8 % vuodessa viimeisten 19 vuoden aikana. Hologicn nettomarginaali 13,8 % on laskenut verrattuna 33,2 %:iin muutama vuosi sitten. Hologicn 12 kuukauden konsensustavoitehinta on 77,52 USD, noin yli kurssia 2,0 %. 23 analyytikosta 0 suosittaa ostoa — kokonaiskonsensus on Pidä.
Hologic osakekurssi
Hologic liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Hologic -osakkeesta
The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.
The business model of Hologic Inc revolves around providing innovative diagnostic solutions, primarily focused on women's healthcare. Hologic develops and markets a wide range of medical devices and instruments, including imaging systems, surgical products, and molecular diagnostic assays. The company's products are designed to enable healthcare professionals to effectively screen, diagnose, and treat various conditions and diseases. Hologic is renowned for its advanced technologies in breast health, gynecology, and skeletal health, offering solutions that empower early detection and intervention. By constantly pushing the boundaries of medical technology, Hologic Inc remains committed to improving healthcare outcomes for women around the world.
Hologic Inc is primarily active in the healthcare industry, specifically in the field of diagnostic products and medical devices. With a focus on improving women's health, Hologic Inc develops and manufactures a wide range of innovative solutions. Their portfolio includes advanced imaging systems, molecular diagnostic assays, surgical instruments, and women's health screening tests. As a prominent player in the healthcare sector, Hologic Inc constantly strives to provide cutting-edge technologies and solutions to address various medical challenges.
Hologic Inc is a leading global healthcare and diagnostics company. Established in 1985, Hologic has excelled in providing innovative solutions for women's health, with a focus on early detection and treatment of breast and cervical cancers. The company's dedication to research and development has resulted in breakthrough technologies, including the introduction of the first 3D mammography system. Hologic has expanded its portfolio to include diagnostics, surgical and skeletal health, and GYN surgical products. With a strong commitment to advancing healthcare, Hologic Inc continues to make significant contributions to improving patient outcomes and quality of life.
Hologic Inc, a leading healthcare company, has achieved several significant milestones. In recent years, the company has made notable advancements in breast health solutions. They introduced the world's first 3D mammography system, which revolutionized breast cancer detection by providing clearer and more accurate images. Hologic Inc also developed the Genius™ 3D Mammography™ exam, proven to detect breast cancer at an earlier stage compared to 2D mammography alone. Furthermore, the company expanded its portfolio by acquiring Gen-Probe, a molecular diagnostics company, allowing Hologic Inc to offer a comprehensive range of diagnostic solutions. These milestones highlight Hologic Inc's commitment to innovation and improving women's healthcare outcomes.
Hologic Inc is primarily present in various countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered. Additionally, Hologic Inc operates in Europe, including countries like Germany, France, Italy, and the United Kingdom. It also has a presence in Asia, particularly in countries such as China and Japan. Furthermore, Hologic Inc serves customers in Canada and Latin America, with a focus on countries like Mexico and Brazil. Overall, Hologic Inc has a global reach and aims to provide its products and services to diverse markets internationally.
Hologic Inc represents values of innovation, commitment to quality, and patient-centric approach. The corporate philosophy of Hologic Inc revolves around developing cutting-edge medical technologies to improve women's health outcomes. With a focus on providing accurate and reliable diagnostic solutions, Hologic Inc strives to empower healthcare professionals and patients alike. The company's dedication to research and development, evidence-based practices, and collaboration with healthcare experts reinforces its commitment to advancing healthcare for women globally. Hologic Inc's mission is to make a difference in people's lives through advanced healthcare solutions, making them a trusted and reliable leader in the industry.
Analyytikot asettavat tällä hetkellä Hologic-osakkeelle keskimääräisen tavoitehinnan 76,66 USD (mediaani: 77,52 USD), mikä merkitsee +0,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 23 analyytikkoarvioon.
23 analyytikkoa arvioi tällä hetkellä Hologic-osaketta: 0 suosittaa ostoa, 20 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Hologic-yhtiöltä 4,24 Mrd. USD liikevaihtoa ja 4,49 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Hologic-osake noteerataan hintaan 67,55 EUR (76,01 USD).
Hologic-osake (HOLX) on listattuna 9 pörssissä, muun muassa: NASDAQ (HOLX), London (0J5Q.L), SIX (Zürich) (HO1.SW), XETRA (HO1.DE), Frankfurt (HO1.F), München (HO1.MU), Düsseldorf (HO1.DU), Wien (HOLX.VI).
Hologic Inc is an international leading provider of medical technology products and solutions. The company, headquartered in Marlborough, Massachusetts, operates globally and is divided into four business segments: Diagnostics, Gynecology, Skeletal Health, and Aesthetics.
odotettu liikevaihto Hologic on 4,24 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Hologic on 1,01 Mrd. USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Hologic:n hinta-voitto-suhde (P/E) on tällä hetkellä 16,93. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Hologic-osakkeen arvostusta.
Hologic:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,05. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Hologic-osakkeen arvostuskennuslukuna.
Hologic:n Eulpool-laatuscore on 1/10.
Hologic:n ISIN on US4364401012. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Hologic:n WKN on 879100. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Hologic:n ticker on HOLX. Tämä pörssinoteeraus käytetään Hologic-osakkeiden kauppaan pörssissä.
Hologic osake
Hologic vertaisryhmä
Hologic Ticker
Hologic FIGI
Kaikki tunnusluvut ja syvällinen analyysi Hologic:sta
Meidän osakeanalyysimme Hologic-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Hologic:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: